Neuromuscular

The chief medical officer and chief operating officer of Brainstorm Cell Therapeutics spoke about a host of topics related to the treatment of amyotrophic lateral sclerosis.

The treatment is the first patient-infused subcutaneous formulation of immunoglobulin to gain approval for CIDP.

Although there is no cure for ALS, there are treatments available that can improve the quality of life and prolong survival.

What neuropsychiatric conditions are relatives of people with ALS at risk for? Are other genes involved besides C9orf72?

Two more novel therapies are quickly following the first approval in 2 decades for ALS.

A genetic mutation suspected to be associated with amyotrophic lateral sclerosis risk has been confirmed through a large-scale research effort.

Serum testing for NMDAR and other autoantibodies is fraught with pitfalls, and careful clinical consideration is important.